2018意大利专家共识声明：优化PD1抑制剂治疗经典霍奇金淋巴瘤.pdfVIP

LEUKEMIA LYMPHOMA /10.10802018.1519808 ORIGINAL ARTICLE: CLINICAL Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma a b c d e f Pier Luigi Zinzani , Armando Santoro , Arturo Chiti , Secondo Lastoria , Antonio Pinto , Lugi Rigacci , g h h Giovanni Barosi , Martina Pennisi and Paolo Corradini a b Institute of Hematology L. e A. Seragnoli, University of Bologna, Bologna, Italy; Department of Oncology and Hematology, IRCCS Humanitas Cancer Center, Milan, Italy; cNuclear Medicine Department, Humanitas Research Hospital and Humanitas University, Milan, Italy; dNuclear Medicine Unit, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, Naples, Italy; eHematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, Naples, Italy; f Department of Hematology, University of Florence, Florence, Italy; gCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; hDivision of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy ABSTRACT ARTICLE HISTORY Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treat- Received 4 April 2018 ment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell Revised 7 August 2018 transplantation (ASCT) and p